Guidelines for the use of MS Contin tablets in the management of cancer pain.

  • 1 January 1991
    • journal article
    • clinical trial
    • p. S9
Abstract
MS Contin (controlled-release oral morphine) has been successfully used to treat moderate to severe pain associated with cancer. The indication for administering MS Contin is not a poor prognosis, but rather pain requiring repeated dosing with potent opioids over periods of more than a few days. Individualization of analgesic dosage to each patient's needs can provide excellent relief of pain in most patients but require selection of the right analgesic in the right dose at the right intervals.

This publication has 0 references indexed in Scilit: